Shaping the Next Era of Cardiac Ablation: Clinical Insights From Early Adopters

Real-world perspectives from PulseSelect™ and Affera™

With lots of new pulsed-field ablation (PFA) technology becoming available, the most important question becomes: How are they performing in the real-world? This session will dive into the lab to share practical perspectives from physicians at the forefront of adoption. Join Dr Jack McCready (University Hospitals Sussex NHS Foundation Trust, UK) as he chairs an insightful session with Dr Richard Balasubramaniam (Royal Bournemouth Hospital, UK) and Dr Sandeep Panikker (University Hospital Coventry, UK) exploring the next era of cardiac pulsed-field ablation (PFA). 

Dr Panikker will share insights from using the PulseSelect™ PFA system. PulseSelect is setting a new standard in safety for paroxysmal and persistent atrial fibrillation ablation, supported by 15 years of robust preclinical and clinical evidence.¹ Dr. Balasubramaniam will share insights from using the Affera mapping and ablation system. The Affera Sphere-9™ introduces an all-in-one solution that combines high-resolution mapping with dual-energy ablation, enabling electrophysiologists to seamlessly transition between pulsed-field and radiofrequency modalities within a single system.

Together, these innovations mark a transformative moment in rhythm management. Attendees will gain insights into how PFA technology is being integrated into daily clinical practice, understand the advantages of dual-energy approaches, and explore how these technologies are redefining efficiency and outcomes in cardiac ablation. 

Don’t miss this opportunity to join these leading experts in a highly engaging discussion, and discover how Affera and PulseSelect are helping to shape the future of electrophysiology!

1. Verma A, Haines DE, Boersma LV, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422–1432.